Rashmi Barbhaiya, CEO of Advinus, is worried about declining interest from large pharmaceutical companies in outsourcing drug discovery and development work to India. While India once seemed well-positioned to become a major center for pharmaceutical innovation due to its educational system, researchers, generics industry, and intellectual property laws, recent court rulings and an unfavorable policy environment have damaged India's reputation and given investors the impression that India is now hostile to pharmaceutical innovation. A broken clinical trials system and other issues have also created a poor research and development ecosystem in India.
Project on Production and Packaging in Pharmaceutical Industry Emcure By Nikh...Nikhil Dhawan
This is the Complete Project that I`ve Completed on 7/08/2014 and It is Now Brand New Project Report Suitable for Students doing MBA, PGDBM and Having Topics like Marketing or HR. No Ads, No Price, No Money!
You Can Contact Me for More Free Projects! Just Download the Project and Enjoy! Cheers!!
Best of Luck
Nikhil Dhawan
9018580277, 9622334428
nikdhawan@outlook.com.
contactnikhildhawan@gmail.com.
contact_nikhildhawan@gmail.com
Indian pharmaceutical industry: Policies, achievements and challengesRajesh Kochhar
Indian pharmaceutical industry is a success story from a national as well as third-world perspective. India accounts for 10% of world production and ranks third in the world in terms of volume. In value terms the share is only 1.4% and the rank 14th.
his statistic underlines the important fact that India produces world-class generic drugs at a very low cost. Indian domestic pharma market, currently evaluated at $12 bn, is largely self-sufficient with patented drugs playing a minimal role.
A Know-How Guide to Acquire & Invest in Indian Pharmaceutical Industry.
How can US Pharma Majors gain a sustainable competitive edge in the hyper-competitive market?
Project on Production and Packaging in Pharmaceutical Industry Emcure By Nikh...Nikhil Dhawan
This is the Complete Project that I`ve Completed on 7/08/2014 and It is Now Brand New Project Report Suitable for Students doing MBA, PGDBM and Having Topics like Marketing or HR. No Ads, No Price, No Money!
You Can Contact Me for More Free Projects! Just Download the Project and Enjoy! Cheers!!
Best of Luck
Nikhil Dhawan
9018580277, 9622334428
nikdhawan@outlook.com.
contactnikhildhawan@gmail.com.
contact_nikhildhawan@gmail.com
Indian pharmaceutical industry: Policies, achievements and challengesRajesh Kochhar
Indian pharmaceutical industry is a success story from a national as well as third-world perspective. India accounts for 10% of world production and ranks third in the world in terms of volume. In value terms the share is only 1.4% and the rank 14th.
his statistic underlines the important fact that India produces world-class generic drugs at a very low cost. Indian domestic pharma market, currently evaluated at $12 bn, is largely self-sufficient with patented drugs playing a minimal role.
A Know-How Guide to Acquire & Invest in Indian Pharmaceutical Industry.
How can US Pharma Majors gain a sustainable competitive edge in the hyper-competitive market?
5 companies in the wound healing market to watch for in 2019Avi Surana
The global wound healing market is projected to reach USD 42,069 million by 2024 growing at a CAGR of 6.2%, according to ResearchAndMarkets.com. North America is the largest market for wound care, with U.S alone taking a lion’s share of 38.5% in 2017 while Asia-Pacific is the fastest growing market.
We take a look at some of the companies that are developing novel technologies to address the unmet and growing needs of the wound care market.
To recap the previous month's pharma highlights to Pharma Uptoday followers, Monthly magazine Volume 17 has been released with the following content.
News Uptoday
New Guidance
Audit Findings
483 Observations
EU Non Compliance Report
- INTEGRA LIFE SCIENCES CORP, United States
- JINAN JINDA PHARMACEUTICAL CHEMISTRY CO., LTD., China
- WUXI JIDA PHARMACEUTICAL CO., LTD, China
- PARABOLIC DRUGS LIMITED, India
Warning Letters
- Mahendra Chemicals, India
Regulations of the Month
- Sec. 211.25 Personnel qualifications
- Sec. 211.28 Personnel responsibilities
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015Sathish Vemula
News Uptoday
New Guidance
Audit Findings
- Diabetes Corporation of America
- Pine Pharmaceuticals
Warning Letters
- Warning letter: American Family Pharmacy
- Warning letter: Dr. Reddy's Laboratories Limited
- Warning letter: Sandoz Private Limited
Article of the Month
- Data Integrity Checklist related to Electronic Records and Electronic Signatures.
Regulations of the Month
- Sec. 211.46 Ventilation, air filtration, air heating and cooling
- Sec. 211.48 Plumbing
Sun Pharma - Ranbaxy Merger PresentationDeepak Shenoy
SunPharma and Ranbaxy merge in 2014 to create India's largest and the world's fifth largest pharma company. The merger, which is all stock, will give Ranbaxy shareholders 0.8 Sun Pharma shares for each share they own.
Strategic Analysis of the Indian Pharmaceutical Contract Manufacturing Market...Aiswariya Chidambaram
The Indian Pharmaceutical CMO market has been analyzed and assessed with respect to APIs and finished dose formulations (solids, liquids and injectables). Strategic recommendations for the success of market participants have been provided.
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Irish Pereira
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
Blocks to Creativity and Innovation. Tools to Release Creativity and InnovationMike Cardus
www.create-learning.com
Innovative ideas can be blocked by a certain "stuckness" of habit and environment. In this presentation are several ways to overcome innovation blocks.
5 companies in the wound healing market to watch for in 2019Avi Surana
The global wound healing market is projected to reach USD 42,069 million by 2024 growing at a CAGR of 6.2%, according to ResearchAndMarkets.com. North America is the largest market for wound care, with U.S alone taking a lion’s share of 38.5% in 2017 while Asia-Pacific is the fastest growing market.
We take a look at some of the companies that are developing novel technologies to address the unmet and growing needs of the wound care market.
To recap the previous month's pharma highlights to Pharma Uptoday followers, Monthly magazine Volume 17 has been released with the following content.
News Uptoday
New Guidance
Audit Findings
483 Observations
EU Non Compliance Report
- INTEGRA LIFE SCIENCES CORP, United States
- JINAN JINDA PHARMACEUTICAL CHEMISTRY CO., LTD., China
- WUXI JIDA PHARMACEUTICAL CO., LTD, China
- PARABOLIC DRUGS LIMITED, India
Warning Letters
- Mahendra Chemicals, India
Regulations of the Month
- Sec. 211.25 Personnel qualifications
- Sec. 211.28 Personnel responsibilities
Pharma Uptoday Monthly Magazine Volume 21; Issue Dec 2015Sathish Vemula
News Uptoday
New Guidance
Audit Findings
- Diabetes Corporation of America
- Pine Pharmaceuticals
Warning Letters
- Warning letter: American Family Pharmacy
- Warning letter: Dr. Reddy's Laboratories Limited
- Warning letter: Sandoz Private Limited
Article of the Month
- Data Integrity Checklist related to Electronic Records and Electronic Signatures.
Regulations of the Month
- Sec. 211.46 Ventilation, air filtration, air heating and cooling
- Sec. 211.48 Plumbing
Sun Pharma - Ranbaxy Merger PresentationDeepak Shenoy
SunPharma and Ranbaxy merge in 2014 to create India's largest and the world's fifth largest pharma company. The merger, which is all stock, will give Ranbaxy shareholders 0.8 Sun Pharma shares for each share they own.
Strategic Analysis of the Indian Pharmaceutical Contract Manufacturing Market...Aiswariya Chidambaram
The Indian Pharmaceutical CMO market has been analyzed and assessed with respect to APIs and finished dose formulations (solids, liquids and injectables). Strategic recommendations for the success of market participants have been provided.
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Irish Pereira
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
Blocks to Creativity and Innovation. Tools to Release Creativity and InnovationMike Cardus
www.create-learning.com
Innovative ideas can be blocked by a certain "stuckness" of habit and environment. In this presentation are several ways to overcome innovation blocks.
101 Business Insights is the first business networking site that rewards members for their time and input. As a member you get real, asset-backed rewards for commenting, posting or even simply hanging out at the site. It’s our way of thanking you for engaging with and growing the network, and for being part of the most vibrant business community on the net.
Creativity isn't just for artists, musicians, writers, and designers. We all have the ability to be excellent creative thinkers. - https://www.milestechnologies.com
Ready, Set, Present (Creativity PowerPoint Presentation Content): 100+ PowerPoint presentation content slides. Creativity adds to everyone’s personal and professional bottom line and is where innovation and excellence begins. Creativity PowerPoint Presentation Content slides include topics such as: understanding creativity as a human skill using mini systems and processes, the benefits of creativity, left and right brain thinking, blocks to creativity, organizational success through creativity, over techniques, methods, examples and exercises. There are 9 slides covering the definition of creativity, 10 slides on how creative mind works followed by 14 slides describing the process of creativity, creative people and their qualities. Within the first 43 slides you will discover connection between creativity and organizational success and ways to increase your personal creativity. In addition you will receive 19 slides of unique information about fostering organizational creativity, 23 slides covering management and group creativity as well as 11 slides about creativity and the future plus much more.
Current regulatory challenges in indian pharmaceutical industryVikas Rathee
India is the 3rd largest in terms of volume and 13th in terms of value all over the world as we still struggle in terms of quality so in this ppt i show some challenges faced by Indian Pharmaceutical Industry
Present Status and Scope of Pharmaceutical industry in IndiaMadhuraNewrekar
The Indian pharmaceutical industry came into existence in 1901, when Bengal Chemical & Pharmaceutical Company started its maiden operation in Calcutta.
The next few decades saw the pharmaceutical industry moving through several phases, largely in accordance with government policies. The development, present status and scope of pharmaceutical industry in India.
Introduction Indian Pharmaceutical market, SWOT analysis, PEST Analysis, Timeline analysis of Sun Pharma, Glaxo Smith Kline, Mankind, CIPLA and Zydus Cadila.
May 2015 Edition of BEACON, A Monthly Newsletter by SIMCON.
Inside this issue:
About Us
Our Team
INDUSTRY ANALYSIS : Pharmaceutical Industry
COMPANY ANALYSIS : Sun Pharma
BRAND ANALYSIS : Kellogg's
Concept of the month
Discover the innovative and creative projects that highlight my journey throu...dylandmeas
Discover the innovative and creative projects that highlight my journey through Full Sail University. Below, you’ll find a collection of my work showcasing my skills and expertise in digital marketing, event planning, and media production.
An introduction to the cryptocurrency investment platform Binance Savings.Any kyc Account
Learn how to use Binance Savings to expand your bitcoin holdings. Discover how to maximize your earnings on one of the most reliable cryptocurrency exchange platforms, as well as how to earn interest on your cryptocurrency holdings and the various savings choices available.
Navigating the world of forex trading can be challenging, especially for beginners. To help you make an informed decision, we have comprehensively compared the best forex brokers in India for 2024. This article, reviewed by Top Forex Brokers Review, will cover featured award winners, the best forex brokers, featured offers, the best copy trading platforms, the best forex brokers for beginners, the best MetaTrader brokers, and recently updated reviews. We will focus on FP Markets, Black Bull, EightCap, IC Markets, and Octa.
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.AnnySerafinaLove
This letter, written by Kellen Harkins, Course Director at Full Sail University, commends Anny Love's exemplary performance in the Video Sharing Platforms class. It highlights her dedication, willingness to challenge herself, and exceptional skills in production, editing, and marketing across various video platforms like YouTube, TikTok, and Instagram.
Building Your Employer Brand with Social MediaLuanWise
Presented at The Global HR Summit, 6th June 2024
In this keynote, Luan Wise will provide invaluable insights to elevate your employer brand on social media platforms including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok. You'll learn how compelling content can authentically showcase your company culture, values, and employee experiences to support your talent acquisition and retention objectives. Additionally, you'll understand the power of employee advocacy to amplify reach and engagement – helping to position your organization as an employer of choice in today's competitive talent landscape.
buy old yahoo accounts buy yahoo accountsSusan Laney
As a business owner, I understand the importance of having a strong online presence and leveraging various digital platforms to reach and engage with your target audience. One often overlooked yet highly valuable asset in this regard is the humble Yahoo account. While many may perceive Yahoo as a relic of the past, the truth is that these accounts still hold immense potential for businesses of all sizes.
Implicitly or explicitly all competing businesses employ a strategy to select a mix
of marketing resources. Formulating such competitive strategies fundamentally
involves recognizing relationships between elements of the marketing mix (e.g.,
price and product quality), as well as assessing competitive and market conditions
(i.e., industry structure in the language of economics).
Company Valuation webinar series - Tuesday, 4 June 2024FelixPerez547899
This session provided an update as to the latest valuation data in the UK and then delved into a discussion on the upcoming election and the impacts on valuation. We finished, as always with a Q&A
Understanding User Needs and Satisfying ThemAggregage
https://www.productmanagementtoday.com/frs/26903918/understanding-user-needs-and-satisfying-them
We know we want to create products which our customers find to be valuable. Whether we label it as customer-centric or product-led depends on how long we've been doing product management. There are three challenges we face when doing this. The obvious challenge is figuring out what our users need; the non-obvious challenges are in creating a shared understanding of those needs and in sensing if what we're doing is meeting those needs.
In this webinar, we won't focus on the research methods for discovering user-needs. We will focus on synthesis of the needs we discover, communication and alignment tools, and how we operationalize addressing those needs.
Industry expert Scott Sehlhorst will:
• Introduce a taxonomy for user goals with real world examples
• Present the Onion Diagram, a tool for contextualizing task-level goals
• Illustrate how customer journey maps capture activity-level and task-level goals
• Demonstrate the best approach to selection and prioritization of user-goals to address
• Highlight the crucial benchmarks, observable changes, in ensuring fulfillment of customer needs
Taurus Zodiac Sign: Unveiling the Traits, Dates, and Horoscope Insights of th...my Pandit
Dive into the steadfast world of the Taurus Zodiac Sign. Discover the grounded, stable, and logical nature of Taurus individuals, and explore their key personality traits, important dates, and horoscope insights. Learn how the determination and patience of the Taurus sign make them the rock-steady achievers and anchors of the zodiac.
Serious trouble to indian pharma innovation over patents
1. Serious trouble to Indian Pharma Innovation OVER
PATENTS
To any visitor in its Bangalore campus, Advinus would appear to be a healthy company. Its
offices are plush, laboratories state-of-the art, coffers full. It has recently signed a $36-milliion
deal—as minimum payments—for drug discovery with the Japanese firm Takeda, which was
one of the largest deals struck by a pharma services firm anywhere in the world. Advinus, a
contract research firm belonging to the Tata Group, has other multinational clients too, and a
healthy pipeline of its own drug compounds for such a small company. Yet its founder-CEO
Rashmi Barbhaiya is worried. In recent times, large pharma companies have ostensibly
expressed little desire in using India as a base for drug discovery or development. It is
becoming harder and harder to get companies to outsource to India. For over a decade,
Barbhaiya had been a champion of Indian capabilities in drug discovery and development. He
believed, like many other industry veterans did till recently, that India could become one of the
world centres for drug discovery and development. The country seemed to have everything
going right at that time. It had a good educational system, an expanding pool of researchers, a
globally-competitive generics industry, a reputation for services, and a set of high-quality.
One serious flaw in its innovation system, its intellectual property laws, seemed to have been
fixed by 2005, although through external pressure. The outlook for domestic pharma innovation,
however, has become less hopeful in recent times. “My customers always ask me: why is it that
we get strong tail winds in China and face strong headwinds in India?” says Barbhaiya. The
recent patent judgment against Novartis, though insignificant by itself, may seem like the
proverbial straw that broke the camel’s back. In fact, industry insiders agree privately that
Novartis had a weak case, and that the Supreme Court had shown considerable insight and
expertise in its judgment. However, the Indian pharma innovation system was at a breaking
point when the judgment came. Compulsory licensing, a defunct system of clinical trials, a
strident generics industry, a series of patent revokes and a set of overactive NGOs had all
combined to give the impression that India no longer valued pharma innovation. “The world has
given too many frivolous patents,” says Kiran Mazumdar-Shaw, chair of Biocon, “and India
should veer away from that. But we should also not get carried away and create an atmosphere
hostile to innovation.”
2. A Poor R&D Ecosystem
The next few years will also show the seriousness of India’s regulators on fixing the broken
clinical trials system, without which the Indian pharmaceutical industry has little chance of
success in the long term. India’s approach to patent disputes may have a bearing on how
several other countries view drug patent cases. But patents may not form the most critical part
of the innovation ecosystem. And Indian pharma companies—by extension, even the
multinationals—are worried about the other components of this ecosystem. The situation in
India is bad for R&D not because of its laws but because of the clinical trials issue. There are
many other problems too. Getting new cell lines for research takes time. So would procuring
important chemicals regularly used in research. India is perhaps the only country—among those
with a decent research tradition—where a company has to wait for three years to do a trial on a
dog. The patent issue, when it comes on top of all this, appears to be more important than it is,
according to many industry insiders.
Yet, patents form a small part of the environment necessary to create a business based on
innovation. “There are many factors other than patents that are now impeding the drug
discovery business in India,” says VN Balaji, a drug discovery consultant and former chief
scientific mentor of Jubilant Biosys, a drug discovery services company. Unlike in all other
countries, Indian pharma innovation is now built almost exclusively through partnerships. Two
decades of domestic drug discovery and development have not resulted in many commercial
drugs, and the large Indian pharmaceutical companies now rely a lot on out-licensing, in-
licensing, or joint projects for drug discovery and development. The services companies have
been beaten squarely by China on the pure-services business model; their business model now
depends much on sharing the risk and developing drugs jointly and not just on plain-vanilla
services.
Patents And Indian Industry
More than two decades ago, when negotiations began for framing the ground rules for
membership in the World Trade Organization (WTO), there was little interest among the
developing countries to include intellectual property rights (IPR) in the discussions. However,
the pharmaceutical industry pressured the US government into including minimum standards in
IPR laws as key to WTO membership. “All developed countries, with the exception of the US,
3. allowed product patents only when their industries were ready,” says Sudip Choudhuri,
professor at the Indian Institute of Management in Calcutta, whose work was quoted extensively
in the Novartis judgment. “India is clearly not ready to allow them.” Here is a quick list: Germany
allowed product patents in 1967, Switzerland in 1977, Italy in 1978, Austria in 1987, and Spain
in 1992. While signing the TRIPs agreement under duress, developing countries negotiated
flexibility in their IPR laws in several aspects. This meant that, although WTO members were to
give product patents for drugs and agricultural chemicals, they were also free to provide
compulsory licensing during national emergencies or put in additional sections in the patent acts
to prevent ever-greening. Patent offices, as always, were free to interpret whether the
innovations satisfied the criteria for patents. Regulators were also free to define national
emergencies in their own ways. India, still smarting under the belief that it was forced to sign an
unfair system, now seems determined to exploit these flexibilities to the fullest possible
extent. The current hostility—real or perceived—to a rigorous product patent regime for drugs
would have hurt Indian industry directly if the country had a thriving innovation ecosystem.
Unlike in the IT industry, India is not a destination for pharma multinationals for R&D. Only Astra
Zeneca and Bristol Myers-Squib (BMS) have invested in drug discovery R&D in India so far.
Astra Zeneca recently closed its Indian drug discovery programme, leaving BMS as the only
company to have done some direct investments in India (See graphic: Domestic Firms Spend.
There is no indication that a rigorous IPR regime would have done otherwise. On the other
hand, few Indian company executives had shared the courage and conviction of the late Anji
Reddy and tried to discover drugs in India entirely on their own. What remains, both currently
and for the future, are partnerships where Indian and overseas companies share the intellectual
property and markets. Drug discovery services began in India in the mid-1990s. Biocon was a
pioneer when it set up Syngene in 1994 to offer services related to drug development. Indian
pharma industry observers then believed that this business presented a great opportunity for the
country, but it didn’t develop as imagined. No formal estimations exist about this market either in
India or China, but industry insiders estimate it to be around Rs 3,000 crore in India and three or
four times bigger in China. However, Indian companies quickly moved beyond plain services—
called ‘full time equivalent’ (FTE) services in industry jargon—and looked for ways of sharing the
risk as well as the reward in drug discovery services, and not just development. So many
services companies—Aurigene, Jubilant Biosys and Advinus are examples—now depend for
their revenues on substantial milestone payments rather than payments for the number of
people who worked on a project. Negotiating a milestone payment is quite different from
4. negotiating an FTE-based business, as there is a big leap of faith involved for the customer.
Many Indian companies have managed to get this leap of faith. Patent cases have not eroded
this trust so far, and could do so in the future only if the courts turn activist.
On reasonable Healthcare
Cost caution
Prices will rise as new drugs hit the market and fewer drugs go off
patent every year
Patented drugs form only 1% of the market for drugs in India, and so it does not require a genius
to figure out that the impact of patents on Indian healthcare is minimal. As more and more drugs
are patented in India, and as they get launched in the country with patent protection, the cost of
healthcare could go up gradually over the decade, just the way generics have gradually reduced
the cost of prescription drugs in the US. Will they put medicines beyond the reach of most people
in the country? Industry observers and analysts predict a rise in drug costs over the next decade
as more cancer drugs come into the market, and fewer drugs go off patent every year.
The US Food and Drug Administration (FDA) approved 39 new drugs last year, the highest
number since 1997. Three of those are now priced at over $200,000 (about Rs 1 crore) a year.
Some of these drugs are for rare diseases, but anti-cancer drugs form a good portion of the new
drugs approved. Anti-cancer drugs are also among the most expensive classes of drugs, and it
remains to be seen how companies price them in India. But it now seems that the low productivity
of the last decade is now giving way to a decade of high productivity for new drugs. High drug
prices are almost certain to follow, and India may not be an exception. The department of
pharmaceuticals is drafting a formula to price Rs 25,000 crore worth of patented drugs, which
might end the constant irritant for global drug makers of incessant compulsory licensing by the
government. The government thinks such licenses won’t be needed once a pricing policy is in
place, and so Big Pharma has so far not complained about this idea.